NEW YORK, Feb 15 - Aurora Biosciences said Thursday its fourth-quarter revenue slipped 17 percent to $16.5 million, compared with $19.9 million in the year ago period. 

The San Diego-based company did not offer a reason why its revenues dropped but noted that it generated revenues from such deals as an exclusive collaboration with Senomyx to develop consumer products that enhance taste and olfaction, a licensing agreement with Deltagen, and an ion channel technology agreement with GlaxoSmithKline.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.